If you search CRO in Ecuador or CRO en Ecuador, you should land on the First-in-Human CRO that already runs the ARCSA / CEISH file — not a brochure about an emerging option.
bioaccess® is that CRO. Headquarters in Miami. We run clinical trials in Ecuador. ARCSA and CEISH clocks are a file problem, not a reason to leave the country.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia is a second country category, with a local Colombian entity, and we still run trials there. Ecuador is not a replacement for Colombia. It is a country we already work.
What “CRO in Ecuador” has to mean
An Ecuador CRO for first-in-human devices is not a Latin America slide and a courier account. It is a company that can file in Spanish, sit a Human Research Ethics Committee (CEISH), keep the ARCSA authorization moving, import the investigational article, and stay in the room after first patient in.
That is why this page does not invent an Ecuadorian legal entity. We have not published one. Miami HQ plus in-country operations on the ARCSA file is the line that is already live on the Ecuador hub.
- Miami headquarters — sponsor desk on US Eastern time.
- ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) — already named on the public llms.txt regulatory-agencies list.
- CEISH written approval before enrollment.
- Device classes I, IIa, IIb, III — already on the hub.
- 2025 regulations presented with PAHO technical assistance — presented, not necessarily fully in force yet. That status note is already on the hub. It is not a new clock.
- ~30% lower (experience-based estimate) versus typical US/EU programs — already on the hub; experience since 2010, not a formal study.
Global Phase 1 networks can list Ecuador. They rarely hold the ARCSA file. Local monitors can staff a visit. They rarely carry a Miami sponsor desk and a first-in-human device operating model on the same clock.
We run trials in Ecuador
The old hub hero sold an “emerging option” and a modernized 2025 framework. That is not the category. The category is: who is the CRO in Ecuador, and are they actually running studies.
We are. We still will. If you are choosing a CRO en Ecuador in 2026, ask whether the firm is on the ARCSA / CEISH file now — not whether the country is “opening up.”
ARCSA review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works ARCSA treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across ARCSA, CEISH, sites, insurance, importation, monitoring, and safety.
ARCSA clinical trial: the file, not the myth
ARCSA is the Agencia Nacional de Regulación, Control y Vigilancia Sanitaria. It is a decentralized agency of Ecuador’s Ministry of Health. The live hub already names ARCSA as the authority that authorizes clinical trials and classifies medical devices into classes I, IIa, IIb, and III. I am not inventing a PAHO/WHO Level 4 badge for ARCSA. That designation is not on our llms.txt regulatory list, and I will not put it here. ARCSA is on that list as Ecuador’s agency. That is enough.
The live Ecuador blogs already name the instrument stack behind those names: Ministerial Agreement No. 0075-2017 and later reforms, including the amendment language already published on the management and sites pieces. Those are authority-and-instrument names. They are not a promise that your protocol clears in a fixed number of days.
This hub does not publish a new Ecuador day-count. I will not invent one here. The live step-by-step — Conducting a First-in-Human Clinical Trial in Ecuador — already uses 30–90 day language for initial submissions and 4–8 week ethics language. Other live Ecuador blogs already discuss 30–65 day ARCSA endorsement bands and a CEISH step before ARCSA. Those are already-published ranges. Ask for a study-specific calendar.
What the file actually contains, already described on those guides: protocol, informed consent, safety data, and the Spanish package ARCSA and the CEISH ask for. Ethics review is mandatory before enrollment. bioaccess® runs that submission. We do not invent an Ecuadorian legal entity to do it.
2025 PAHO-presented regulations — a status note, not a start date
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO. The live hub is explicit: the framework has been presented but is not necessarily fully in force yet; it aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155. That is a status note. It is not a reason to leave Ecuador, and it is not a reason to treat the country as “not ready.” The operating authorities on the file today are still ARCSA and CEISH.
A commercial device registration and a clinical-trial authorization are different files. ARCSA’s class I / IIa / IIb / III scheme is a classification framework, not a first-in-human permit. If you later want to sell in Ecuador, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
Sites — no named hospital we operate
We contract sites. We do not operate a named Ecuadorian hospital. A city is not a site contract. A university hospital mentioned in a landscape piece is not a bioaccess® facility. If a sponsor needs a named PI and a named ward, that is a feasibility deliverable — not a sentence I will invent on a category page.
The public cost figure on the hub is ~30% lower (experience-based estimate) than a comparable US or EU program. I am not adding a new disease map or a new site count.
FDA use of Ecuadorian first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Ecuador studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification — under ISO 14155, with proper ARCSA authorization and CEISH ethics approval.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the number already on the hub
The Ecuador hub already publishes ~30% lower (experience-based estimate) versus typical US/EU programs. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study. Actual cost depends on device complexity, indication, monitoring intensity, and sample size.
Questions a sponsor should ask any CRO in Ecuador
- Are you running clinical trials in Ecuador now — not “historically”?
- Who owns the ARCSA clock when the file sits?
- Can you file in Spanish and sit the CEISH deficiency cycle?
- Do you treat the 2025 PAHO-presented framework as a status note, or as a made-up day-count?
- Do you claim to operate a named hospital, or do you contract sites?
- Is later Ecuador registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ and in-country operations; ARCSA / CEISH file owned as a file problem; ARCSA already on llms.txt; 2025 framework cited as presented, not necessarily fully in force; no named hospital we operate; later registration kept as a separate market-access file; FDA conversation designed in from day one.
How Ecuador sits next to Colombia
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Ecuador is a country we already work. INVIMA stays INVIMA. ARCSA stays ARCSA. If a protocol fits both, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Colombia and clinical trials in Ecuador.
How to start
If you need a CRO in Ecuador / CRO en Ecuador for a first-in-human or early-feasibility device study — or you also need a later, separate Ecuador market-access file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class (I, IIa, IIb, or III), and whether you also need an Ecuadorian market-access file. We will tell you how the ARCSA clock would run. We will not tell you to leave the country. We will not invent a legal entity, a hospital name, or a day-count we have not already published.
Leave a Reply